The simple auto-injector platform trusted for use with blockbusters and emerging brands alike
The Owen Mumford Pharmaceutical Services Challenge
Anaphylaxis is a serious and severe allergic reaction that affects the whole body; it is often life threatening, and in severe cases, the cardiovascular system can completely collapse. Although anaphylaxis is treated with an intramuscular injection of adrenaline into the thigh, it still kills 0.65%-2.0% of patients who experience and episode.1 The main cause of anaphylactic fatalities is the late injection of adrenaline, which leaves symptoms to worsen resulting in death.2
If patients use a device that consistently performs, this not only reduces wasted of medicine, but increases patient confidence
Common mistakes patients make when injecting include: not removing the safety cap, operating the device upside down, injecting into the arm, and not pressing the device hard enough to deploy the needle and adrenaline.3
The new Anapen® 2 was designed to solve the problems training alone could not. The Autoject® Mini has an established and trusted profile amongst clinicians and patients, and proved an ideal platform for the development project.
If patients use a device that consistently performs, this not only reduces wastage of medicine but increases patient confidence. This allows the patient to manage their anaphylaxis more pro-actively by using their device and injecting as appropriate, rather than waiting for symptoms to worsen.
1. Frew AJ. What are the ideal features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy 2011; 66:15–24
2. Schwirtz A, Seegar H. Comparison of the robustness and functionality of three adrenaline auto-injectors. Journal of Asthma and Allergy 2012; 5:39–49
3. Lombardelli S. (2010, June) Adrenaline auto-injectors: how effective are written patient instructions when used alone in a simulated self-administrration test? Presented at Exhibition Hall, Hungerford UK